jpolicano

SalioGen Therapeutics Announces Closing of $20 Million Series A Financing to Support Advancing a Novel Genome Engineering Platform for Non-Viral Gene Therapy

SalioGen Therapeutics Announces Closing of $20 Million Series A Financing to Support Advancing a Novel Genome Engineering Platform for Non-Viral Gene Therapy Introducing a mammal-derived genome engineering enzyme for next-generation gene and cell therapy Financing to fund SalioGen’s pipeline in genetic diseases, based on proprietary EDIT ‘gene coding’ platform to advance durable, safe and affordable …

SalioGen Therapeutics Announces Closing of $20 Million Series A Financing to Support Advancing a Novel Genome Engineering Platform for Non-Viral Gene Therapy Read More »